INT171361

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.62
First Reported 2002
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 16
Total Number 17
Disease Relevance 8.36
Pain Relevance 0.81

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endosome (Egfr) cell morphogenesis (Egfr) Golgi apparatus (Egfr)
endoplasmic reticulum (Egfr) intracellular (Egfr) enzyme binding (Egfr)
Anatomy Link Frequency
A549 1
Egfr (Mus musculus)
Pain Link Frequency Relevance Heat
MU agonist 12 98.84 Very High Very High Very High
agonist 24 98.40 Very High Very High Very High
Opioid 69 98.16 Very High Very High Very High
Neurotransmitter 4 88.68 High High
addiction 12 87.52 High High
metalloproteinase 4 74.84 Quite High
palliative 12 73.56 Quite High
opioid receptor 36 69.00 Quite High
Pain 12 55.44 Quite High
antagonist 44 48.96 Quite Low
Disease Link Frequency Relevance Heat
Cancer 700 99.84 Very High Very High Very High
Lung Cancer 94 99.64 Very High Very High Very High
Pancreatic Cancer 134 99.16 Very High Very High Very High
Non-small-cell Lung Cancer 217 98.84 Very High Very High Very High
Hypoxia 45 98.84 Very High Very High Very High
Death 13 98.40 Very High Very High Very High
Apoptosis 53 97.00 Very High Very High Very High
Malignant Neoplastic Disease 29 96.44 Very High Very High Very High
Metastasis 57 96.40 Very High Very High Very High
Glioma 42 95.48 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
This might provide a rationale to down regulate EGFR, thus improving chemosensitivity.
Regulation (regulate) of EGFR
1) Confidence 0.62 Published 2005 Journal Genet Vaccines Ther Section Body Doc Link PMC1187910 Disease Relevance 0.43 Pain Relevance 0
ResultsSignificant down-regulation of EGFR gene expression with siRNA specific for EGFR
Regulation (regulation) of EGFR
2) Confidence 0.45 Published 2005 Journal Genet Vaccines Ther Section Body Doc Link PMC1187910 Disease Relevance 0.40 Pain Relevance 0
To determine the effects of EGFR inhibition in vivo and to examine their consequences, we implanted SQ20B cells subcutaneously in nude mice.
Spec (determine) Regulation (effects) of EGFR
3) Confidence 0.44 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2716529 Disease Relevance 0.64 Pain Relevance 0
These factors were not addressed in the other studies and could potentially account for the differences in EGFR and EGFRvIII prognostic impact between these studies, especially if there was a significant incidence of these in a small series.
Regulation (differences) of EGFR
4) Confidence 0.42 Published 2005 Journal J Transl Med Section Body Doc Link PMC1298339 Disease Relevance 0.95 Pain Relevance 0.07
There has been considerable interest in targeting the EGFR pathway in advanced pancreatic cancer with agents such as erlotinib currently in the limelight.
Regulation (targeting) of EGFR associated with pancreatic cancer
5) Confidence 0.41 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1936363 Disease Relevance 0.86 Pain Relevance 0.04
Furthermore, inducing down-regulation of either the EGFR or ?
Regulation (regulation) of EGFR
6) Confidence 0.35 Published 2002 Journal BMC Pharmacol Section Body Doc Link PMC88976 Disease Relevance 0.18 Pain Relevance 0.27
Specifically, key protein intermediates may be physically associated with endogenous RTKs in HEK-293 cells, and therefore, down-regulation of the EGFR may negatively affect ERK phosphorylation by opioids.
Regulation (regulation) of EGFR associated with opioid
7) Confidence 0.35 Published 2002 Journal BMC Pharmacol Section Body Doc Link PMC88976 Disease Relevance 0.06 Pain Relevance 0.16
To examine this, we induced significant down-regulation of EGFR density and function by exposing ?
Regulation (regulation) of EGFR
8) Confidence 0.35 Published 2002 Journal BMC Pharmacol Section Body Doc Link PMC88976 Disease Relevance 0.06 Pain Relevance 0.13
Krause et al. provided evidence that increased oxygenation after targeting of the EGFR by C225 might contribute to the improvement in local control following radiation [34].
Regulation (targeting) of EGFR
9) Confidence 0.26 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2716529 Disease Relevance 0.67 Pain Relevance 0
Another important consideration with regards to the mode of action of EGFR inhibitors such as erlotinib is that whilst these drugs have been designed to target the EGFR, it appears that quantification of the target per se in preclinical models may not predict for responsiveness to inhibition.
Regulation (target) of EGFR
10) Confidence 0.25 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1936363 Disease Relevance 0.38 Pain Relevance 0.04
The two main therapeutic modalities used to target the EGFR are monoclonal antibodies against the extracellular domain and small molecules tyrosine kinase inhibitors (TKIs) that compete at the ATP binding site of the tyrosine kinase domain (Table 1).
Regulation (target) of EGFR
11) Confidence 0.25 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1936363 Disease Relevance 0.44 Pain Relevance 0
Erlotinib is a small molecule HER-1/EGFR inhibitor that blocks dysregulated EGFR-mediated intracellular signalling in NSCLC, inhibiting proliferation and permitting apoptosis of malignant cells.
Regulation (dysregulated) of EGFR-mediated associated with malignant neoplastic disease, non-small-cell lung cancer and apoptosis
12) Confidence 0.23 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012552 Disease Relevance 0.76 Pain Relevance 0.06
Molecules targeting the EGFR, such as erlotinib, gefitinib, and cetuximab, form an important component of novel treatment approaches in combination with docetaxel for the treatment of SCCHN.
Regulation (targeting) of EGFR
13) Confidence 0.22 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621396 Disease Relevance 0.41 Pain Relevance 0
Novel approaches to target the EGFR in cancer include the diminution of EGFR expression using interfering molecules and antibodies; in fact, several recent preclinical studies have investigated the potential of EGFR in pre-transcriptional inhibition of the EGFR gene to enhance the activity of conventional chemotherapeutic agents (Niwa et al 2003; Nozawa et al 2006).
Regulation (target) of EGFR associated with cancer
14) Confidence 0.22 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621396 Disease Relevance 0.75 Pain Relevance 0
Alteration of the EGFR/HER-2 receptors and downstream signaling cascades by lapatinib results in apoptosis induction in A549 cells
Regulation (Alteration) of EGFR in A549 associated with apoptosis
15) Confidence 0.22 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2883966 Disease Relevance 0.45 Pain Relevance 0
Cholesterol by modulating caveolae formation regulates several signaling molecules like AKT, IGFR, EGFR and Rho which are involved in cell growth and survival.
Regulation (regulates) of EGFR
16) Confidence 0.14 Published 2008 Journal Gene Regulation and Systems Biology Section Abstract Doc Link PMC2745153 Disease Relevance 0.91 Pain Relevance 0
Presynaptic Type III Neuregulin1-ErbB signaling targets ?
Regulation (targets) of ErbB
17) Confidence 0.08 Published 2008 Journal The Journal of Cell Biology Section Title Doc Link PMC2364689 Disease Relevance 0 Pain Relevance 0.04

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox